Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Viking Therapeutics, Inc. Director's Dealing 2021

Jun 10, 2021

31359_dirs_2021-06-10_ef87b096-0e43-4bf5-b7f9-ce234bb03821.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Viking Therapeutics, Inc. (VKTX)
CIK: 0001607678
Period of Report: 2021-06-10

Reporting Person: FOEHR MATTHEW W (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-06-10 Common Stock, par value $0.00001 per share P 20000 $5.69 Acquired 66250 Direct